神经胶质瘤肿瘤干细胞表面标记物及相关靶向治疗研究进展
Research Progress on Surface Markers of Glioma Cancer Stem Cells and Related Targeted Therapeutic Strategies
DOI: 10.12677/jcpm.2025.43328, PDF,   
作者: 胡长义*：济宁医学院临床医学院(附属医院)，山东 济宁；李 波#：济宁医学院附属医院神经外科，山东 济宁
关键词: 神经胶质瘤(Glioma)；CD133；SSEA-1；Nestin；A2B5；Glioma； CD133； SSEA-1； Nestin； A2B5
摘要: 神经胶质瘤目前是神经系统最常见的颅内恶性肿瘤，其具有高度侵袭性、预后差、易复发、对放化疗有抵抗性等特点。目前对于提高神经胶质瘤的分级及预后评价的准确性及有效性，胶质瘤干细胞表面标记物具有十分重要的意义。本文主要对CD133、SSEA-1、Nestin、A2B5等干细胞表面标记物在胶质瘤的诊治中的特征与联系进行了综述。当前研究提示，CD133是目前被认为与胶质母细胞瘤最密切相关的生物标记物，虽然目前对于其生物学意义仍有不同观点，但现在越来越多的研究证实CD133参与了胶质瘤干细胞介导的肿瘤形成。与之相比较对SSEA-1、Nestin、A2B5等标记物的研究尚不完善，但其弥补了CD133的部分短板。这几种表面标记物为胶质瘤的临床靶向治疗上提供了重要的理论依据。
Abstract: Glioma, the most prevalent intracranial malignancy in the central nervous system, is characterized by high invasiveness, poor prognosis, frequent recurrence, and resistance to radiotherapy and chemotherapy. The identification of glioma stem cell (GSC) surface markers holds critical significance for improving the accuracy and efficacy of glioma grading and prognostic evaluation. This review systematically summarizes the characteristics and clinical relevance of stem cell surface markers, including CD133, SSEA-1, Nestin, and A2B5, in glioma diagnosis and treatment. Current evidence highlights CD133 as the most extensively studied biomarker closely associated with glioblastoma pathogenesis. Although its biological significance remains controversial, accumulating studies confirm CD133's pivotal role in GSC-mediated tumorigenesis. In contrast, investigations into SSEA-1, Nestin, and A2B5 remain nascent, yet these markers address certain limitations of CD133. Collectively, these surface markers provide a robust theoretical foundation for developing targeted therapeutic strategies against glioma.
文章引用：胡长义, 李波. 神经胶质瘤肿瘤干细胞表面标记物及相关靶向治疗研究进展[J]. 临床个性化医学, 2025, 4(3): 155-161. https://doi.org/10.12677/jcpm.2025.43328

参考文献

[1] Ostrom, Q.T., Cioffi, G., Waite, K., Kruchko, C. and Barnholtz-Sloan, J.S. (2021) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. Neuro-Oncology, 23, iii1-iii105. [Google Scholar] [CrossRef] [PubMed]
[2] 国家卫生健康委员会医政医管局, 中国抗癌协会脑胶质瘤专业委员会, 中国医师协会脑胶质瘤专业委员会. 脑胶质瘤诊疗指南(2022版) [J]. 中华神经外科杂志, 2022, 38(8): 757-777。
[3] Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J.B., et al. (2005) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine, 352, 987-996. [Google Scholar] [CrossRef] [PubMed]
[4] Tran, B. and Rosenthal, M.A. (2010) Survival Comparison between Glioblastoma Multiforme and Other Incurable Cancers. Journal of Clinical Neuroscience, 17, 417-421. [Google Scholar] [CrossRef] [PubMed]
[5] Ostrom, Q.T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., et al. (2013) CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010. Neuro-Oncology, 15, ii1-ii56. [Google Scholar] [CrossRef] [PubMed]
[6] Dawood, S., Austin, L. and Cristofanilli, M. (2014) Cancer Stem Cells: Implications for Cancer Therapy. Oncology (Williston Park), 28, 1101-1107, 1110.
[7] Corbeil, D., Röper, K., Weigmann, A. and Huttner, W.B. (1998) AC133 Hematopoietic Stem Cell Antigen: Human Homologue of Mouse Kidney Prominin or Distinct Member of a Novel Protein Family? Blood, 91, 2625-2626. [Google Scholar] [CrossRef] 
[8] Miraglia, S., Godfrey, W. and Buck, D. (1998) A Response to AC133 Hematopoietic Stem Cell Antigen: Human Homologue of Mouse Kidney Prominin or Distinct Member of a Novel Protein Family? Blood, 91, 4390-4391. [Google Scholar] [CrossRef] 
[9] Kleinlützum, D., Hanauer, J.D.S., Muik, A., Hanschmann, K., Kays, S., Ayala-Breton, C., et al. (2017) Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective. Frontiers in Oncology, 7, Article No. 127. [Google Scholar] [CrossRef] [PubMed]
[10] Zhang, X., Lian, W., Lou, W., Han, S., Lu, C., Zuo, K., et al. (2016) Transcatheter Arterial Infusion of Autologous CD133(+) Cells for Diabetic Peripheral Artery Disease. Stem Cells International, 2016, Article ID: 6925357. [Google Scholar] [CrossRef] [PubMed]
[11] Singh, S.K., Clarke, I.D., Terasaki, M., et al. (2003) Identification of a Cancer Stem Cell in Human Brain Tumors. Cancer Research, 63, 5821-5828.
[12] Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., et al. (2004) Identification of Human Brain Tumour Initiating Cells. Nature, 432, 396-401. [Google Scholar] [CrossRef] [PubMed]
[13] Beier, D., Hau, P., Proescholdt, M., Lohmeier, A., Wischhusen, J., Oefner, P.J., et al. (2007) CD133+ and CD133− Glioblastoma-Derived Cancer Stem Cells Show Differential Growth Characteristics and Molecular Profiles. Cancer Research, 67, 4010-4015. [Google Scholar] [CrossRef] [PubMed]
[14] Brescia, P., Ortensi, B., Fornasari, L., Levi, D., Broggi, G. and Pelicci, G. (2013) CD133 Is Essential for Glioblastoma Stem Cell Maintenance. Stem Cells, 31, 857-869. [Google Scholar] [CrossRef] [PubMed]
[15] Lim, S.H., Jang, J., Park, J.O., et al. (2014) CD133-Positive Tumor Cell Content Is a Predictor of Early Recurrence in Colorectal Cancer. Journal of Gastrointestinal Oncology, 5, 447-456.
[16] You, H., Ding, W. and Rountree, B.C. (2010) Epigenetic Regulation of Cancer Stem Cell Marker CD133 by Transforming Growth Factor-β. Hepatology, 51, 1635-1644. [Google Scholar] [CrossRef] [PubMed]
[17] Fukamachi, H., Shimada, S., Ito, K., Ito, Y. and Yuasa, Y. (2011) CD133 Is a Marker of Gland‐Forming Cells in Gastric Tumors and Sox17 Is Involved in Its Regulation. Cancer Science, 102, 1313-1321. [Google Scholar] [CrossRef] [PubMed]
[18] Liu, A., Yu, Q., Peng, Z., Huang, Y., Diao, S., Cheng, J., et al. (2017) miR-200b Inhibits CD133(+) Glioma Cells by Targeting the AKT Pathway. Oncology Letters, 13, 4701-4707. [Google Scholar] [CrossRef] [PubMed]
[19] Hambardzumyan, D., Squartro, M. and Holland, E.C. (2006) Radiation Resistance and Stem-Like Cells in Brain Tumors. Cancer Cell, 10, 454-456. [Google Scholar] [CrossRef] [PubMed]
[20] Georgia, S., Soliz, R., Li, M., Zhang, P. and Bhushan, A. (2006) P57 and Hes1 Coordinate Cell Cycle Exit with Self-Renewal of Pancreatic Progenitors. Developmental Biology, 298, 22-31. [Google Scholar] [CrossRef] [PubMed]
[21] Chang, C., Liu, W., Hung, H., Gean, C., Tsai, H., Su, C., et al. (2017) Synergistic Inhibition of Tumor Growth by Combination Treatment with Drugs against Different Subpopulations of Glioblastoma Cells. BMC Cancer, 17, Article No. 905. [Google Scholar] [CrossRef] [PubMed]
[22] Ding, B., James, D., Iyer, R., Falciatori, I., Hambardzumyan, D., Wang, S., et al. (2013) Prominin 1/CD133 Endothelium Sustains Growth of Proneural Glioma. PLOS ONE, 8, e62150. [Google Scholar] [CrossRef] [PubMed]
[23] Yang, L., Yan, Z., Wang, Y., Ma, W. and Li, C. (2016) Down‐Expression of Mir‐154 Suppresses Tumourigenesis in Cd133+ Glioblastoma Stem Cells. Cell Biochemistry and Function, 34, 404-413. [Google Scholar] [CrossRef] [PubMed]
[24] Kim, J.S., Shin, D.H. and Kim, J. (2018) Dual-Targeting Immunoliposomes Using Angiopep-2 and CD133 Antibody for Glioblastoma Stem Cells. Journal of Controlled Release, 269, 245-257. [Google Scholar] [CrossRef] [PubMed]
[25] Liu, X., Wu, W., Wu, W., Yin, F., Ma, S., Qin, J., et al. (2013) A Minority Subpopulation of CD133(+)/EGFRvIII(+)/EGFR(-) Cells Acquires Stemness and Contributes to Gefitinib Resistance. CNS Neuroscience & Therapeutics, 19, 494-502. [Google Scholar] [CrossRef] [PubMed]
[26] Jamal, M., Rath, B.H., Tsang, P.S., Camphausen, K. and Tofilon, P.J. (2012) The Brain Microenvironment Preferentially Enhances the Radioresistance of CD133+ Glioblastoma Stem-Like Cells. Neoplasia, 14, 150-158. [Google Scholar] [CrossRef] [PubMed]
[27] Ahmed, E.M., Bandopadhyay, G., Coyle, B. and Grabowska, A. (2018) A HIF-Independent, CD133-Mediated Mechanism of Cisplatin Resistance in Glioblastoma Cells. Cellular Oncology, 41, 319-328. [Google Scholar] [CrossRef] [PubMed]
[28] Son, M.J., Woolard, K., Nam, D., Lee, J. and Fine, H.A. (2009) SSEA-1 Is an Enrichment Marker for Tumor-Initiating Cells in Human Glioblastoma. Cell Stem Cell, 4, 440-452. [Google Scholar] [CrossRef] [PubMed]
[29] Lin, W., Modiano, J.F. and Ito, D. (2017) Stage-Specific Embryonic Antigen: Determining Expression in Canine Glioblastoma, Melanoma, and Mammary Cancer Cells. Journal of Veterinary Science, 18, 101-104. [Google Scholar] [CrossRef] [PubMed]
[30] Lendahl, U., Zimmerman, L.B. and McKay, R.D.G. (1990) CNS Stem Cells Express a New Class of Intermediate Filament Protein. Cell, 60, 585-595. [Google Scholar] [CrossRef] [PubMed]
[31] Matsuda, Y., Hagio, M. and Ishiwata, T. (2013) Nestin: A Novel Angiogenesis Marker and Possible Target for Tumor Angiogenesis. World Journal of Gastroenterology, 19, 42-48. [Google Scholar] [CrossRef] [PubMed]
[32] Czekierdowska, S., Stachowicz, N., Chróściel, M. and Czekierdowski, A. (2017) Proliferation and Maturation of Intratumoral Blood Vessels in Women with Malignant Ovarian Tumors Assessed with Cancer Stem Cells Marker Nestin and Platelet Derived Growth Factor PDGF-B. Ginekologia Polska, 88, 120-128. [Google Scholar] [CrossRef] [PubMed]
[33] Krüger, K., Wik, E., Knutsvik, G., Nalwoga, H., Klingen, T.A., Arnes, J.B., et al. (2017) Expression of Nestin Associates with BRCA1 Mutations, a Basal-Like Phenotype and Aggressive Breast Cancer. Scientific Reports, 7, Article No. 1089. [Google Scholar] [CrossRef] [PubMed]
[34] Strojnik, T., Røsland, G.V., Sakariassen, P.O., Kavalar, R. and Lah, T. (2007) Neural Stem Cell Markers, Nestin and Musashi Proteins, in the Progression of Human Glioma: Correlation of Nestin with Prognosis of Patient Survival. Surgical Neurology, 68, 133-143. [Google Scholar] [CrossRef] [PubMed]
[35] Dahlrot, R.H., et al. (2013) What Is the Clinical Value of Cancer Stem Cell Markers in Gliomas. International Journal of Clinical and Experimental Pathology, 6, 334-348.
[36] Sun, T., Chen, G., Li, Y., Xie, X., Zhou, Y. and Du, Z. (2015) Aggressive Invasion Is Observed in CD133−/A2B5+ Glioma-Initiating Cells. Oncology Letters, 10, 3399-3406. [Google Scholar] [CrossRef] [PubMed]
[37] Veerkamp, J.H. and Zimmerman, A.W. (2001) Fatty Acid-Binding Proteins of Nervous Tissue. Journal of Molecular Neuroscience, 16, 133-142. [Google Scholar] [CrossRef] [PubMed]
[38] Arai, Y., Funatsu, N., Numayama-Tsuruta, K., Nomura, T., Nakamura, S. and Osumi, N. (2005) Role of fabp7, a Downstream Gene of Pax6, in the Maintenance of Neuroepithelial Cells during Early Embryonic Development of the Rat Cortex. The Journal of Neuroscience, 25, 9752-9761. [Google Scholar] [CrossRef] [PubMed]
[39] Jia, H.E., et al. (2015) Aquaporin 1 Expression in Glioma Patients and Its Potential Function in Glioma Progression. Chinese Journal of Clinical Oncology, 43, 493.
[40] McCoy, E. and Sontheimer, H. (2007) Expression and Function of Water Channels (Aquaporins) in Migrating Malignant Astrocytes. Glia, 55, 1034-1043. [Google Scholar] [CrossRef] [PubMed]
[41] Warth, A., Mittelbronn, M., Hülper, P., Erdlenbruch, B. and Wolburg, H. (2007) Expression of the Water Channel Protein Aquaporin-9 in Malignant Brain Tumors. Applied Immunohistochemistry & Molecular Morphology, 15, 193-198. [Google Scholar] [CrossRef] [PubMed]
[42] Bello, L., Francolini, M., Marthyn, P., Zhang, J., Carroll, R.S., Nikas, D.C., et al. (2001) Αvβ3 and Αvβ5 Integrin Expression in Glioma Periphery. Neurosurgery, 49, 380-390. [Google Scholar] [CrossRef] 
[43] 艾文兵, 刘学勇, 熊志云, 等. 整合素αvβ3对胶质瘤细胞增殖和侵袭力影响的实验研究[J]. 中华肿瘤防治杂志, 2007, 14(19): 1450-1453.
[44] Ogden, A.T., Waziri, A.E., Lochhead, R.A., Fusco, D., Lopez, K., Ellis, J.A., et al. (2008) Identification of A2B5+CD133− Tumor-Initiating Cells in Adult Human Gliomas. Neurosurgery, 62, 505-515. [Google Scholar] [CrossRef] [PubMed]
[45] 汪庆, 李炎炎, 韩笑笑, 等. 建立人源A2B5+/CD133−的胶质瘤亚群干细胞样细胞株的实验研究[J]. 中国细胞生物学学报, 2018, 40(7): 1101-1110.
[46] Xia, C., Du, Z., Liu, Z., Huang, Q. and Chan, W. (2003) A2B5 Lineages of Human Astrocytic Tumors and Their Recurrence. International Journal of Oncology, 23, 353-361. [Google Scholar] [CrossRef] 
[47] Xu, M., Yao, Y., Hua, W., Wu, Z., Zhong, P., Mao, Y., et al. (2014) Mouse Glioma Immunotherapy Mediated by A2B5+ GL261 Cell Lysate-Pulsed Dendritic Cells. Journal of Neuro-Oncology, 116, 497-504. [Google Scholar] [CrossRef] [PubMed]